Pentagon adds WuXi AppTec to military ties list, threatening access to $500B market

The Department of Defense's updated Section 1260H list now includes 188 Chinese entities, with major biotech contractor WuXi AppTec caught in the crossfire of US-China decoupling.

Share

Add us on Google by Editorial Team Jun. 9, 2026

The US Department of Defense just made life significantly harder for one of the world’s largest pharmaceutical contract manufacturers. WuXi AppTec, the Shanghai-based firm that helps develop and produce drugs for a huge swath of the global pharma industry, has been added to the Pentagon’s list of companies with alleged ties to the Chinese military.

The June 2026 update to the Section 1260H list, which identifies Chinese military companies operating in the United States, brings the total number of designated entities to 188. WuXi AppTec joins a fresh batch of additions that also includes Alibaba, Baidu, BYD, RoboSense, and Unitree. The company, which employs approximately 1,900 people across eight US states, says the designation is wrong and plans to fight it.

What the designation actually does

Being named doesn’t automatically freeze assets or ban transactions. What it does is restrict the Department of Defense from procuring goods and services from these companies, and it sends a signal to every other US government agency and private contractor that doing business with the listed entity carries risk.

The DoD cited WuXi AppTec’s alleged indirect ownership by China’s State-Owned Assets Supervision and Administration Commission, known as SASAC, along with affiliations with military-related entities. WuXi has pushed back forcefully, pointing to its US-based operations, local job creation, and community investments as evidence that the designation mischaracterizes the company’s role and purpose.

Advertisement

This isn’t even the first time WuXi landed on this list. An earlier expanded version in February 2026 included the company, but that update was withdrawn within hours. No explanation was provided for the reversal.

Why biotech is ground zero for US-China decoupling

WuXi AppTec is a contract research, development, and manufacturing organization, often called a CDMO, that serves as critical infrastructure for the global pharmaceutical supply chain. When a biotech startup or even a major pharma giant needs molecules synthesized, clinical trials supported, or manufacturing scaled, firms like WuXi are where they turn.

The BIOSECURE Act, which has been driving congressional scrutiny of Chinese biotech firms, reflects growing anxiety that too much of America’s drug development pipeline runs through companies that could, in theory, be compelled to share sensitive data with Beijing.

Congressional letters had previously urged the Pentagon to add WuXi to the military-linked entity list, suggesting this move didn’t come out of nowhere.

What this means for investors

US pharmaceutical companies and biotech firms that currently rely on WuXi AppTec’s services now face a difficult calculation. Continuing the relationship means potential scrutiny from regulators, complications with government contracts, and the risk that future legislation could make the partnership untenable.

WuXi AppTec has stated it will contest the designation, but challenging Pentagon determinations is a slow, uncertain process. The February withdrawal and subsequent re-listing suggests the decision-making around these designations is itself unstable.

With 188 entities now on the list, any company with significant Chinese supply chain exposure faces the possibility of disruption. US-based CDMOs and those operating in allied nations could benefit as pharmaceutical companies look for alternatives.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.